Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 495-501

  Thomas, Michael ^a   Mousa, Shaymaa S ^b   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aflibercept; Anti VEGF; Bevacizumab; Pegatanib; Ranibizumab; VEGF; VIEW trials

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; COMPARATIVE EFFECTIVENESS; CORNEA NEOVASCULARIZATION; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EYE DISEASE; EYE IRRITATION; EYE REDNESS; HUMAN; INJECTION SITE REACTION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; VASCULOTROPIN GENE; VISUAL ACUITY; WET AGE RELATED MACULAR DEGENERATION;

EID: 84874874434     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S29974     Document Type: Review

References (50)

1. Haddrill M. Macular degeneration treatment [webpage on the Internet]. San Diego, CA: Access Media Group LLC; 2011 [updated Nov 2011; cited Oct 2012]. Available from: http://www.allaboutvision.com/conditions/amd-treatments.htm. Accessed October 23, 2012.
2. About macular degeneration [webpage on the Internet]. Sarasota, FL: Macular Degeneration Association; 2011 [cited October 26, 2012]. Available from: http://www.maculardegenerationassociation.org/about-md/. Accessed February 25, 2013.
3. MedlinePlus: Verteporfin injection [webpage on the Internet]. Bethesda, MD: US National Library of Medicine [updated September 1, 2010]. Available from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607060.html. Accessed February 25, 2013.
4. Ahn JC, Chung PS. The activity of G-ROS and the predominant role of Type II reaction in the photodynamic therapy using 9-hydroxypheophorbide-alpha for HeLa cell lines. Gen Physiol Biophys. 2012;31(3):343-350.
5. Yoo JJ, Kim C, Chung CW, Jeong YI, Kang DH. 5-aminolevulinic acid-incorporated poly(vinyl alcohol) nanofiber-coated metal stent for application in photodynamic therapy. Int J Nanomedicine. 2012;7: 1997-2005.
6. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761-774.
7. Chen Y, Han F. Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Ther Clin Risk Manag. 2012;8:343-351.
8. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175-1186.
9. Chen E, Brown DM, Wong TP, et al. Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol. 2010;4:1073-1079.
10. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
11. Aflibercept (Eylea) for age-related macular degeneration [webpage on the Internet]. New Rochelle, NY: The Medical Letter, Inc; 2012 [updated February 6, 2012]. Available from: http://secure.medicalletter.org/TML-article-1383a. Accessed November 13, 2012.
12. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
13. NEI: National Eye Institute [homepage on the Internet]. Bethesda, MD: National Institutes of Health [updated Sep 2009]. Available from: http://www.nei.nih.gov/. Accessed November 13, 2012.
14. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
15. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica. 2012;227 Suppl 1:2-10.
16. Facts about age-related macular degeneration [webpage on the Internet]. Bethesda, MD: National Institutes of Health; 2009 [updated Sep 2009]. Available from: http://www.nei.nih.gov/health/maculardegen/armd_facts.asp. Accessed November 13, 2012.
17. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227 Suppl 1:30-35.
18. Costagliola C, Agnifili L, Arcidiacono B, Duse S, Fasanella V, Mastropasqua R, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2012;12(10): 1299-1313.
19. Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37(12):1171-1174.
20. Golik P, Tońska K. Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents - on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klin Oczna. 2012;114(1): 79-83. Polish.
21. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2): 171-185.
22. Verner-Cole EA, Davis SJ, Lauer AK. Aflibercept for the treatment of neovascular age-related macular degeneration. Drugs Today (Barc). 2012;48(5):317-329.
23. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227 Suppl 1:11-20.
24. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother. 2012;13(4):585-591.
25. Nork TM, Dubielzig RR, Christian BJ, et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol. 2011;129(8): 1042-1052.
26. Ida H, Tobe T, Nambu H, Matsumura M, Uyama M, Campochiaro PA. RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. Invest Ophthalmol Vis Sci. 2003;44(12):5430-5437.
27. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol. 2012;227(1):116-126.
28. Jarrett SG, Boulton ME. Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med. 2012;33(4):399-417.
29. Sparrow JR, Ueda K, Zhou J. Complement dysregulation in AMD: RPE-Bruch's membrane-choroid. Mol Aspects Med. 2012;33(4): 436-445.
30. Couch SM, Bakri SJ. Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol. 2011;26(3): 114-120.
31. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870.
32. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25(6):661-672.
33. Figurska M, Robaszkiewicz J, Wierzbowska J. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis. Klin Oczna. 2010;112(4-6):147-150.
34. Traynor K. Aflibercept approved for macular degeneration. Am J Health Syst Pharm. 2012;69(1):6.
35. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-270.
36. Regeneron Pharmaceuticals. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 1). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2007 [updated December 20, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00509795. NLM identifer: NCT00509795. Accessed November 13, 2012.
37. Bayer. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2) In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated February 27, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00637377. NLM identifer: NCT00637377. Accessed November 13, 2012.
38. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
39. Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012;29(10):839-846.
40. Nguyen QD, Campochiaro PA, Shah SM, et al; Clear-It 1 Investigators. Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2012;28(6):581-588.
41. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434-457.
42. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IbeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47(10):4569-4578.
43. Jackson TL, Kirkpatrick L. Cost comparison of ranibizumab and bevacizumab. BMJ. 2011;343:d5058.
44. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6:12.
45. Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688-693.
46. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244-1246.
47. Lang GE. Diabetic macular edema. Ophthalmologica. 2012;227 Suppl 1:21-29.
48. Bandello F, Berchicci L, La Spina C, Battaglia Parodi M, Iacono P. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res. 2012;48 Suppl 1:16-20.
49. Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME (Protocol T). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated August 21, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01627249. NLM identifier: NCT01627249. Accessed November 14, 2012.
50. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028-1043.